‘Inactive’ Label Doesn’t Make Cannabinoids Less Active Or Clear Their Use In OTC Drugs In US

FDA warns BioLyte Laboratories and Honest Globe about making OTC drugs with cannabinoids. Firms also advised about GMP problems and that labeling cannabinoids as inactive ingredients doesn’t  make their use compliant.

Consumer health products containing cannabinoids and deemed unapproved drugs in the US aren’t limited to products marketed as dietary supplements. The Food and Drug Administration has warned a contract manufacturer and another firm about making OTC drugs with cannabinoids.

The firms, BioLyte Laboratories LLC and Honest Globe Inc

Additionally, the letters published on 22 March warned the firms about good manufacturing practices

More from Archive

More from HBW Insight